Screener
Nektar Therapeutics NKTR CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of investments | (452,253) | (24,931) |
| Maturities of investments | 101,482 | 69,319 |
| Purchases of property and equipment | (18) | (2) |
| Payment of transaction costs and working capital adjustment from the sale of the Huntsville manufacturing facility | - | (697) |
| Net cash provided by (used in) investing activities | (350,789) | 43,689 |
| Cash flows from financing activities: | ||
| Proceeds from shares issued under equity compensation plans | 4,055 | 7 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's capex?
- Nektar Therapeutics (NKTR) reported capex of $18K in Q1 2026.
- How has Nektar Therapeutics's capex changed year-over-year?
- Nektar Therapeutics's capex increased by 800.0% year-over-year, from $2K to $18K.
- What is the long-term trend for Nektar Therapeutics's capex?
- Over 4 years (2021 to 2025), Nektar Therapeutics's capex has grown at a -67.3% compound annual growth rate (CAGR), from $14.99M to $171K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Nektar Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude